View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 26, 2020

Quidel gets expanded emergency use authorisation for SARS-CoV-2 test

The US Food and Drug Administration (FDA) has granted expanded emergency use authorisation (EUA) for Quidel’s Lyra SARS-CoV-2 Assay for the coronavirus (Covid-19) diagnosis.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.


The US Food and Drug Administration (FDA) has granted expanded emergency use authorisation (EUA) for Quidel’s Lyra SARS-CoV-2 Assay for the coronavirus (Covid-19) diagnosis.

The expanded EUA will enable testing with three additional thermocyclers – Applied Biosystems 7500 Standard, Roche LightCycler 480 and Qiagen Rotor-Gene Q.

The initial EUA allowed the Lyra SARS-CoV-2 assay real-time RT-PCR test to qualitatively detect nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of Covid-19 by their healthcare provider.

Recently, the Centers for Disease Control and Prevention (CDC) expanded the list of acceptable specimens to include nasal and nasal turbinate swabs.

The FDA grants EUA to enable the early availability of important diagnostic tools when there are no adequate, approved and available alternatives.

The Lyra reagents are characterised by features that allow simple transport and storage, enhanced workflow, quicker results and other benefits that positively affect the diagnostic test outcome.

The test also provides certain additional advantages, including easier set-up and faster test results compared to other tests currently on the market for the coronavirus.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high-complexity tests.

Meanwhile, the Lyra SARS-CoV-2 Assay received CE-Mark, allowing its market launch in Europe and other countries.

Quidel also obtained authorisation from Health Canada to market and sell the assay in Canada. The assay is currently available for sale in the US under the EUA.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network